JE05 Rec'd PCT/PTC 2 9 NOV 2001 ORIGINAL

FORM PTO-1390 U.S. DEPARTMENT OF COM (REV. 11-2000)							
TRANSMITTAL LETTER	TRANSMITTAL LETTER TO THE UNITED STATES						
	ED OFFICE (DO/EO/US)	U.S. APPLICATION NO. (If known, see 37 CFR 1.5					
CONCERNING A FILIN	CONCERNING A FILING UNDER 35 U.S.C. 371						
INTERNATIONAL APPLICATION NO. PCT/EP00/04417	INTERNATIONAL FILING DATE 16 May 2000 (16.05.00)	PRIORITY DATE CLAIMED 29 May 1999 (29.05.99)					
TITLE OF INVENTION SUBSTITUTED P	HENYLCYCLOHEXANE CARBOXYLIC ACI	D AMIDES THAT HAVE AN ADENOSINE					
UPTAKE INHIBITING EFFECT							
APPLICANT(S) FOR DO/EO/US FREUND, et al.							
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:							
1. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.							
	 2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. X This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include 						
items (5), (6), (9) and (21) indicated below.							
4. X The US has been elected by the expiration of 19 months from the priority date (Article 31). 5. X A copy of the International Application as filed (35 U.S.C. 371(c)(2))							
a v is attached hereto (required only if not communicated by the International Bureau)							
b. has been communicated by	b. has been communicated by the International Bureau.						
c. is not required, as the appli	c. is not required, as the application was filed in the United States Receiving Office (RO/US).						
	An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).						
a. X is attached hereto.							
b. has been previously submitted under 35 U.S.C. 154(d)(4).							
Amendments to the claims of the International Aplication under PCT Article 19 (35 U.S.C. 371(c)(3)) a. are attached hereto (required only if not communicated by the International Bureau).							
nave been communicated by the international Bureau.							
	c. have not been made; however, the time limit for making such amendments has NOT expired.						
. ==	d. X have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).						
An oath or declaration of the inventor		ie 17 (33 0.0.0. 311 (e)(3)).					
<u> </u>		vamination Report under PCT					
10. An English lanugage translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).							
Items 11 to 20 below concern document(s) or information included:							
11. X An Information Disclosure Stateme	nt under 37 CFR 1.97 and 1.98.						
	ling. A separate cover sheet in compliance w	with 37 CFR 3.28 and 3.31 is included.					
13. X A FIRST preliminary amendment.							
14. A SECOND or SUBSEQUENT pre	eliminary amendment.						
15. A substitute specification.							
16. A change of power of attorney and/	or address letter.						
17. A computer-readable form of the se	quence listing in accordance with PCT Rule	13ter.2 and 35 U.S.C. 1.821 - 1.825.					
18. A second copy of the published inte	A second copy of the published international application under 35 U.S.C. 154(d)(4).						
19. A second copy of the English langu	A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).						
20. X Other items or information:1) Certificate of Mailing under 37 C.F.R. 1.10; 2) Transmittal of Information Disclosure Statement under 37 C.F.R. 1.97(b); 3) Information Disclosure Citation (Modified Form PTO-1449) and references cited therein 4) Return Receipt Postcard.							
Date of Deposit: 29 November 2001 Express Mail Label No.: ET386113124US							

U.S. APPICA JOHNO GILE	On 0-32-74-53 International application no. PCT/EP00/04417				ATTORNEY'S DOCKET NUMBER Le A 33 469		
21. X The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):				CAI	LCULATIONS	PTO USE ONLY	
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO\$1000.00							
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO							
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO							
International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)							
International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)				\$ 80		T	
Surcharge of \$130.00 for furnishing the oath or declaration later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(e)).						 	
CLAIMS	NUMBER FILE	D NUMBER EXTRA	RATE	\$			
Total claims	21 - 20	1	x \$18.00	\$ 18	3.00		
Independent claims	12 - 3		x \$80.00 84.00		6.00	ļ	
MULTIPLE DEPEN			+ \$ 270.00 280.00			<u> </u>	
Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$ 1,5 \$	944.00		
SUBTOTAL =				\$ 1,9	944.00	 	
Processing fee of \$130.00 for furnishing the English translation later than 20 30 anonths from the earliest claimed priority date (37 CFR 1.492(f)).							
TOTAL NATIONAL FEE =				\$ 1,9	944.00		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$			
TOTAL FEES ENCLOSED =					944.00	<u> </u>	
					unt to be efunded:	\$	
<u> </u>	<u> </u>		j		charged:	\$	
a. A check in the amount of \$ to cover the above fees is enclosed. b. Please charge my Deposit Account No. 13-3372 in the amount of \$ 1,944.00 to cover the above fees. A duplicate copy of this sheet is enclosed. c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 13-3372 . A duplicate copy of this sheet is enclosed. d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card							
information should not be included on this form. Provide credit card information and authorization on PTO-2038. NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.							
SEND ALL CORRESPONDENCE TO:				<u> </u>	F. Jenes		
	<i>W</i> .				- T. Bug	·	
Vice President Patents and Licensing		\					
Bayer Corporation William			r. Gl	ay			
West Haven CT 06516							
			REGISTRATION NUMBER				
			REGISTRA	· · · · · ·	· O.HIDDI		

PATENT

Attorney's Docket No. Le A 33 469

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Freund, et al.

Serial No.: National Stage Filing of PCT/EP00/04417

Filed: herewith

For Substituted Phenylcyclohexane Carboxylic Acid Amides that have an Adenosine Uptake

Inhibiting Effect

BOX PCT Assistant Commissioner for Patents Washington, D.C. 20231

CERTIFICATE OF MAILING UNDER 37 CFR 1.10

I hereby certify that the attached correspondence comprising:

- Transmittal Letter to the United States Designated/Elected Office (DO/EO/US)
 Concerning a Filing under 35 U.S.C. 371 [IN DUPLICATE];
- Preliminary Amendment;
- Oath or Declaration of the Inventors (35 U.S.C. 371(c)(4));
- English Translation of the Application;
- Copy of the International Application as filed (35 U.S.C. 371(c)(2));
- Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98 consisting of Transmittal of Information Disclosure Statement under 37 C.F.R. 1.97(b), Information Disclosure Citation (Modified Form PTO-1449) and copies of references cited therein; and
- Return Receipt Post Card.

is, on the date shown below, being deposited with the United States Postal Service, in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number ET386113124US, addressed to:

Box PCT Assistant Commissioner for Patents Washington, D.C. 20231

November 29, 2001

Date

Signature di Person Certifying / Beatriz Alviz